Intrexon Completes Acquisition of Okanagan Specialty Fruits
Healthy Produce Choices for Consumers With Benefits Across Entire Supply Chain GERMANTOWN, Md., April 20, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has completed the acquisition of Okanagan Specialty Fruits (OSF), the pioneering agricultural company behind the Arctic® apple, the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives. OSF's vision and ground-breaking effort in responsibly harnessing the power of technology to produce wholesome, nutritious food that is more appetizing and convenient to consumers is aligned with Intrexon's strategy in the Food sector. The combi...
Driving Sustainable Agriculture through Improved Qualities in Eucalyptus and Poplar Trees
Intrexon and FuturaGene Collaborate to Develop Unique Attributes and Agronomic Properties in Significant Plant Species GERMANTOWN, Md. and SAO PAULO, April 15, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and FuturaGene Group, a wholly owned subsidiary of Suzano Papel e Celulose S.A., the second largest producer of eucalyptus pulp in the world, today announced they have entered into an exclusive collaboration to increase biomass in eucalyptus and poplar trees. FuturaGene has established itself as a leader in the development of sustainable solutions for global forestry, biofuel and agricultural markets through its proficiency in taking optimal tra...
ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono
BOSTON and GERMANTOWN, Md., March 30, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM. Under the collaboration Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its agreeme...
Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy
- Chimeric Antigen Receptor T-cell (CAR-T) therapy enhances Merck Serono's R&D technology portfolio in immuno-oncology - Collaboration and license agreement will focus on developing a next generation CAR-T platform to generate several drug candidates GERMANTOWN, Md., March 30, 2015  /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and Merck Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono's comprehensive, science-driven stra...
1